Bay Area biotech files plans for IPO as it works to treat lung-scarring disease

The South San Francisco company hopes to follow in the footsteps of three other Bay Area life science companies who have had strong debuts on Wall Street this year which has been dominated by offerings from that sector in its first four months.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.